Congress·In Committee·S. 2062

Senate Bill Would Require 6-Month Drug Stockpiles to Prevent Critical Shortages

RAPID Reserve Act

9 months ago·View on Congress.gov

Part of: Congress Proposes $500M for National Drug Reserves to Combat Shortages

⏸

Stalled

No legislative action in over 90 days.

Legislative Progress

Senate

House

President

Law

Key Points

Congress would have Health and Human Services pay drug makers and partners to keep rolling reserves of certain “critical” drugs and ingredients.
Companies would generally need to keep about a 6-month supply of both the drug ingredient and the finished drug, and replace it with newly made stock regularly.
In a shortage or emergency, Health and Human Services could direct production and could direct where some of the ingredient stockpile is sent to help make more finished medicine.
The program would prefer U.S.-based manufacturing and U.S.-sourced materials (or from certain partner countries) to reduce reliance on fragile supply chains.
The bill authorizes $500 million for 2026 and requires regular reports to Congress on which drugs are covered and how well the program works.

HealthcarePrescription DrugsNational Security

Impact Analysis

Personal Impact

How this policy affects specific groups of people

Positive Impacts(2)

Chronic Illness

Helps

Disability Benefits

Helps

Milestones

2 milestones2 actions

Jun 12, 2025Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Jun 12, 2025

Introduced in Senate

What Happens Next

Projected impacts based on AI analysis

Within 180 days after the bill becomes law

HHS and FDA issue program guidance (how drugs are chosen, who qualifies, and what winners must do).

Manufacturers learn the rules to apply, and patients/providers get early signals about which medicines might be prioritized for reserves.

After guidance is issued and as contracts are planned

HHS publishes the list of “critical” drugs and ingredients with vulnerable supply chains.

You can check whether medicines you rely on are included, which is key to whether this program could reduce shortages for you.

Months after the bill becomes law (timing depends on funding and contracting)

HHS awards contracts/cooperative agreements to eligible manufacturers, ingredient makers, and/or distributors.

Selected companies begin building and managing rolling reserves and may expand capacity; non-selected companies may not see support.

Begins after awards; ongoing thereafter

Rolling reserves are built and then continually refreshed with recently made supply.

Over time, shortages of the covered drugs should become less frequent or less severe, especially during sudden demand spikes.

Only when an emergency/disaster triggers the authority

During a public health emergency or major disaster, HHS can direct where certain ingredient reserves go.

Supplies could be redirected to where need is highest, which may help patients overall but could change what’s available in a given region temporarily.

2 years after the first contract/cooperative agreement award

First effectiveness report to Congress is submitted.

Public information should improve on which drugs are covered and whether the program is actually preventing shortages.

Related News

3 articles

Fierce Pharma·9 months ago

Senators bring back bill to bolster US pharma supply chain by awarding contracts to domestic producers

The RAPID Reserve Act would require HHS to award contracts to U.S.-based drugmakers to maintain 6-month reserves of critical medications and ingredients. The bipartisan bill aims to address chronic drug shortages and reduce national security threats from overreliance on foreign suppliers.

Becker's Hospital Review·9 months ago

Senate bill aims to rebuild drug manufacturing infrastructure: 3 notes

Reintroduced by a bipartisan group of senators, the RAPID Reserve Act directs HHS to contract with manufacturers for 6-month stockpiles of essential generic drugs. The bill seeks to address chronic shortages that have left some medications unavailable for over a decade.

Fierce Pharma·4 months ago

Lawmakers dig in on biopharma manufacturing with bill proposing US center of excellence

Lawmakers highlighted the RAPID Reserve Act as a key legislative component in a broader strategy to improve pharmaceutical preparedness. The bill focuses on building domestic reserves and surge capacity to prevent national security threats from drug shortages.